Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04962958 | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | completed | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05653271 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | completed | Phase 1 | 16 | Acepodia Biotech, Inc.INDUSTRY | 3 | Jun 30, 2026 | clinicaltrials |
| NCT06368310 | FIH Clinical Investigation of Graphene Electrodes for Brain Mapping | completed | N/A | 10 | University of ManchesterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06694779 | Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study(PREDIC-TO) | completed | — | 1,504 | Fondazione IRCCS San Gerardo dei TintoriOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07040956 | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. | completed | Phase 2 | 98 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07671495 | Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin(ATSMAIN) | completed | Phase 2 | 278 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT00165256 | Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast | completed | Phase 2 | 157 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 454 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01972347 | Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma(Neo Combi) | completed | Phase 2 | 35 | Melanoma Institute AustraliaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04168788 | Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL(MVO) | completed | N/A | 85 | University Hospital, AngersOTHER_GOV | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04195945 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04526730 | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04566432 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients | completed | — | 252 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05326464 | Tofacitinib in Recurrent GBM Patients | completed | Phase 3 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 30 | Coherus Oncology, Inc.INDUSTRY | 4 | Jun 29, 2026 | clinicaltrials |
| NCT05363488 | Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | completed | — | 17 | PfizerINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05410509 | "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)" | completed | N/A | 25 | University of Alabama at BirminghamOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673666 | GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)(GliomaAI-A23) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673679 | GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4(GliomaAI-A4) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673692 | GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma(GliomaAI-GBM) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673705 | GliomaAI-Oligo: MRI-Based Detection of IDH Mutant Oligodendroglioma(GliomaAI-Oligo) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00209989 | Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme | completed | Phase 2 | 27 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01209871 | Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01750073 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | completed | Phase 2 | 92 | University of NebraskaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01805076 | MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer | completed | Phase 3 | 319 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02303678 | D2C7 for Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 81 | Darell BignerOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT02856347 | Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin(CMTpostopFDOPA) | completed | N/A | 24 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04292626 | Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose | completed | Phase 1 | 16 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04939324 | Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer(ExOnSite-Pro) | completed | N/A | 30 | University Hospital, LimogesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05455931 | Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)(PROSPER) | completed | — | 73 | Kyowa Kirin Pharmaceutical Development LtdINDUSTRY | 6 | Jun 26, 2026 | clinicaltrials |
| NCT06349239 | Oral Azacitidine Maintenance Post-CPX 351(ORAZ-351) | completed | — | 100 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06366451 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC | completed | Early Phase 1 | 17 | Presage BiosciencesINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670403 | Digital Phenotyping of Psychological Distress in Skin Cancer Patients(DP-SKIN) | completed | — | 500 | West China HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02220894 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | completed | Phase 3 | 1,274 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04469244 | Evaluation of the Use of Radiomics in 18F-FDOPA PET Examinations for the Characterization of Gliomas(RADDOPAG) | completed | — | 1,000 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 30, 2026source: clinicaltrials